

Daily Bulletin

August 4, 2025

- > OPEC+ set to increase oil output to regain market share
- > Almoosa Health Posts Sharp Profit Rebound in 2Q25

OPEC+ set to increase oil output to regain market share


OPEC+ has agreed to raise oil production by 547,000 bpd for September, citing healthy global economy and low inventory levels as the primary drivers behind the increase. This latest increase is part of a broader, phased reversal of earlier output cuts and follows a series of monthly hikes since April, aiming to reclaim market share.

Since April, the eight voluntary members have steadily increased output, starting with 138,000 bpd and escalating to monthly hikes of 411,000 bpd in May, June, and July, followed by 548,000 bpd in August and the 547,000 bpd increase in September. This hike marks the end of the voluntarily agreement that started in January 2024 to cut outputs by 2.2 mn bpd due to sluggish oil demand growth in China and a rise in electric vehicles.

Despite the phased ramp-up in supply, oil prices have remained firm, with oil prices (WTI) closing at USD 67.3/bbl on Aug. 1, 2025, supported by seasonal demand and strategic stockpiling activity, particularly in China.

Amid external pressures, including U.S. President Trump's recent threats of sanctions and tariffs against countries buying Russian oil, especially India, the oil market remains volatile. The eight OPEC+ members will continue holding monthly meetings to assess market trends. Their next meeting is scheduled for September 7.

Global oil prices (USD/bbl)



Source: Bloomberg, anbc research

Required oil output in September ('000 bpd)

Country	Required Quota
Saudi Arabia	9,978
Russia	9,449
Iraq	4,220
UAE	3,375
Kuwait	2,548
Kazakhstan	1,550
Algeria	959
Oman	801

Source: OPEC, anbc research

Almoosa Health posts sharp profit rebound in 2Q25

Almoosa Health reported results for the 2Q25, with revenue rising 22.6% YoY to SAR 349 mn (2Q24: SAR 285 mn), driven by higher inpatient and outpatient volumes, in addition to the expansion of specialty service offerings. Acute Care services remained the largest contributor, accounting for 65.8% of quarterly revenue, followed by Pharmaceuticals (22.4%) and Rehabilitation (11.8%). Acute Care revenue grew 33.4% YoY, supported by improved clinic productivity and growing demand for specialized care. Notably, the total patient volume grew by 13.3% YoY.

Gross profit surged 49.1% YoY to SAR 112.1 mn, driven by the higher patient inflows and expansion, while operating profit grew 129.4% YoY on margin improvements and cost discipline. EBITDA increased 81.8% YoY to SAR 79.1 mn (2Q24: SAR 43.5 mn). Net profit rebounded sharply to SAR 51.8 mn from a SAR 1.3 mn loss in 2Q24, supported by operational efficiency, capacity expansion, sustained demand across key services, and lower finance costs following loan settlement in 1Q25. On a QoQ basis, net profit rose 1.3% (2Q25: SAR 51.8 mn vs. 1Q25: SAR 51.1 mn), with the modest increase reflecting pre-operational costs related to staffing for soon-to-be-launched medical centers. These costs are expected to normalize as facilities ramp up.

Shareholders' equity rose to SAR 1,908.4 mn, with the equity share in the capital structure increasing from 33.7% in 1H24 to 76.2% in 1H25 following IPO proceeds in 1Q25. CAPEX jumped 180.2% YoY to SAR 150.7 mn in 2Q25 (43.2% of revenue), reflecting continued investment in expansion, including the recently opened Al Nakheel Primary Care Center in Al-Ahsa, which is expected to contribute from 4Q25. Full-year CAPEX is projected at SAR 400–450 mn, with a five-year target of SAR 3.1 bn. The Board also approved a dividend of SAR 0.35 per share (SAR 15.5 mn) for 2Q25.


Almoosa is currently trading at a forward P/E (2025e) of 42.1x, which is the highest among the listed healthcare players and higher than the median multiple of 24.8x. The stock has a consensus target price of SAR 140/sh, implying a potential downside of 18%.

Almoosa financials (SAR mn)

	2Q25	2Q24	YoY(%)	1Q25	QoQ(%)
Revenue	349	285	23	323	8
COGS	(237)	(209)	13	(224)	6
Gross profit	112	75	49	99	13
Gross margin (%)	32	26		31	
Operating expense	(58)	(52)	12	(49)	18
Operating profit	54	24	130	50	9
Opt. margin (%)	16	8		16	
Net income	52	-1	4085	51	1
Net margin (%)	15	0		16	
EPS	1.17	-0.30		1.15	

Source: Company financials, anb research

Healthcare sector forward P/E's (2025e)



Source: Bloomberg, anb research

Disclaimer:

This report has been prepared on the basis of information believed to be reliable, but anb capital makes no guarantee, representation or warranty, express or implied, as to the accuracy, correctness or completeness of such information, nor do they accept any responsibility for loss or damage arising in any way (including by negligence) from errors in, or omissions from the information.

This report has been prepared by anb capital for information purposes only and is not and does not form part of nor should be considered advice, recommendation, offer for sale or solicitation of any offer to subscribe for, purchase or sell any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever, and any views or opinions expressed herein are subject to change without notice.

This report and information contained herein, are provided for informational purpose only and does not take into consideration any investment objective, financial situation or particular needs of any recipient and are not designed with the objective of providing information to any particular recipient and only provides general information.